According to the JAMA Journal, neutropenic fever occurs in approximately 30% of cancer patients receiving chemotherapy. It affects more than 60,000 patients annually in the United States. In several studies, the mortality rate of febrile neutropenia is reported from 5.4% to 15%. First-line treatment options for febrile neutropenia include fluoroquinolone monotherapy such as moxifloxacin or ciprofloxacin in combination with amoxicillin/clavulanic acid. The condition is a frequent event in cancer patients taking chemotherapy, several clinical trials are addressing the efficacy of colony-stimulating factors for the prevention and treatment of febrile neutropenia.
The Febrile Neutropenia Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into febrile neutropenia drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for febrile neutropenia. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The febrile neutropenia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from febrile neutropenia.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to febrile neutropenia.
Neutropenia is characterized by lower than normal levels of neutrophils in the blood. Febrile neutropenia is the occurrence of fever during a period of neutropenia. A neutrophil is a white blood cell type which bone marrow primarily makes. It destroys germs which cause infections such as viruses and bacteria. When a patient suffers from neutropenia, their risk of getting an infection is higher than normal. Infections can be transmitted from infectious agents between people or sometimes because of organisms which live in the gut, mouth, or on the skin.
The diagnosis of febrile neutropenia includes blood tests, x-rays, or urine samples. Cancer treatments such as chemotherapy destroy cancer cells along with healthy neutrophils and the bone marrow which makes healthy white blood cells.
The treatment for this condition includes corticosteroids, antibiotics, and granulocyte colony-stimulating factors among others. Antibiotics are the major treatment for febrile neutropenia, administered intravenously to fight the infection. Corticosteroids are prescribed in case of autoimmune conditions. These drugs help in suppressing the body’s immune response which is causing the destruction of neutrophils. Granulocyte colony-stimulating factors are prescribed to promote the production of white blood cells in bone marrow. Several pharma companies and research institutes are developing innovative treatments to manage the condition. Clinical trials are focused on addressing the efficacy of colony-stimulating factors in the prevention and treatment of febrile neutropenia. The increasing clinical trials and changing dynamics are impacting the febrile neutropenia clinical trial landscape significantly.
This section of the report covers the analysis of febrile neutropenia drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for febrile neutropenia.
The drug molecules categories covered under febrile neutropenia pipeline analysis include peptides, recombinant proteins, and small molecules. In a study conducted, Filgrastim significantly reduced the incidence and duration of infection of febrile neutropenia. Filgrastim is a biologic drug specifically a recombinant human granulocyte colony-stimulating factor. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for febrile neutropenia.
The EMR report for the febrile neutropenia drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in febrile neutropenia clinical trials:
Major drugs currently in the drug pipeline are as follows:
The trial is designed to assess the safety of EC-18 in patients having advanced breast cancer receiving low febrile neutropenia risk chemotherapy. The trial is sponsored by Enzychem Lifesciences Corporation and is currently under phase I/II.
The objective of the study is to assess the safety of pegylated rhG-CSF in preventing neutropenia after chemot...
Merck Sharp & Dohme LLC is developing the drug and is currently under phase II. The study is being conducted t...
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Major drugs currently in the drug pipeline are as follows:
EC-18
The trial is designed to assess the safety of EC-18 in patients having advanced breast cancer receiving low febrile neutropenia risk chemotherapy. The trial is sponsored by Enzychem Lifesciences Corporation and is currently under phase I/II.
Pegylated rhG-CSF 100μg/kg
The objective of the study is to assess the safety of pegylated rhG-CSF in preventing neutropenia after chemotherapy in patients with breast cancer. The trial is sponsored by Jiangsu HengRui Medicine Co., Ltd. and is currently under phase II.
caspofungin acetate
Merck Sharp & Dohme LLC is developing the drug and is currently under phase II. The study is being conducted to assess the safety of caspofungin acetate as an empirical therapy in pediatric patients having persistent fever and neutropenia.
The Febrile Neutropenia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for febrile neutropenia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within febrile neutropenia pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share